A hepatitis B virus vaccine demonstration project was conducted in southwest Alaska in 1981-1982 to determine the immunogenicity and efficacy of the vaccine.
A total of 1630 susceptible persons in the Alaskan Native population were vaccinated with the recommended three-dose regimen of plasma-derived hepatitis B vaccine, and 94% demonstrated antibody to hepatitis B surface antigen (anti-HBs) at levels =10 mIU/mL.
After 10 years of follow-up, 76% of those immunized had anti-HBs levels =10 mIU.
During the 10 years following the first dose of vaccine, 13 study participants developed antibody to hepatitis B core antigen (10 vaccine responders, 3 nonresponders), and none developed sustained HBs positivity or had clinical hepatitis.
These data suggest that immunization with hepatitis B vaccine continues to provide high levels of protection from clinical disease for at least 10 years.
Mots-clés Pascal : Hépatite virale B, Virose, Infection, Virus hépatite B, Hepadnaviridae, Virus, Immunoprophylaxie, Vaccination, Evaluation, Efficacité, Dosage, Anticorps, Etude statistique, Homme, Alaska, Etats Unis, Amérique du Nord, Amérique, Appareil digestif pathologie, Foie pathologie
Mots-clés Pascal anglais : Viral hepatitis B, Viral disease, Infection, Hepatitis B virus, Hepadnaviridae, Virus, Immunoprophylaxis, Vaccination, Evaluation, Efficiency, Assay, Antibody, Statistical study, Human, Alaska, United States, North America, America, Digestive diseases, Hepatic disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0237114
Code Inist : 002B30A01C. Création : 11/06/1997.